ForwardVue Pharma的封面图片
ForwardVue Pharma

ForwardVue Pharma

生物技术

A FIRST in class anti-angiogenic compound

关于我们

ForwardVue Pharma is an emerging biopharmaceutical company developing a small synthetic compound caroboxyamidotriazole, that acts via the novel mechanism of ORAI-1 inhibition and can be formulated to deliver potent anti-angiogenic effects for 6-12 months. Carboxyamidotriazole has been administered to over 900 patients systemically to treat advanced cancer thereby allowing more rapid progress to Phase 2 once IND enabling ocular toxicity is completed. ForwardVue Pharma has secured initial seed round funding in order to advance pre-clinical development of potent long acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration.

网站
https://www.forwardvuepharma.com
所属行业
生物技术
规模
2-10 人
总部
Cambridge
类型
私人持股
领域
Ophthalmology

地点

ForwardVue Pharma员工

动态

相似主页

查看职位